儿童耐药结核病的负担与危害

doi:10.3969/j.issn.1000-6621.2018.09.016

中国防痨杂志 ›› 2018, Vol. 40 ›› Issue (9): 989-992.doi: 10.3969/j.issn.1000-6621.2018.09.016

儿童耐药结核病的负担与危害

李洁琼,申阿东()

100045 首都医科大学附属北京儿童医院呼吸感染疾病研究室北京市儿科研究所儿科学国家重点学科教育部儿科重大疾病研究重点实验室儿童呼吸道感染性疾病研究北京市重点实验室

收稿日期:2018-07-02 出版日期:2018-09-10 发布日期:2018-10-17
通信作者: 申阿东 E-mail:shenad16@hotmail.com
基金资助:
首都卫生发展科研专项资金(2016-1-2092)

Burden and detriment of drug-resistant tuberculosis in children

Jie-qiong LI,A-dong SHEN()

Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China

Received:2018-07-02 Online:2018-09-10 Published:2018-10-17
Contact: A-dong SHEN E-mail:shenad16@hotmail.com

摘要/Abstract

摘要：

耐药结核病是严重危害儿童健康的重要疾病之一,确诊困难,存在发现率低、治愈率低、传播率高等诸多问题,是现阶段儿科结核病医生和结核病防控专家面临的主要难题之一。笔者分析国内外关于儿童耐药结核病负担和危害方面的数据,对儿童耐药结核病的负担和危害进行综述,以了解儿童耐药结核病现状,及时解决当前存在的问题。

关键词: 结核, 抗多种药物性, 儿童, 患病代价, 危险性评估, 综述

Abstract:

Drug-resistant tuberculosis is one of the major health problems in children. Due to the difficulties in diagnosis, low detection rate, low cure rate and high transmission rate, drug-resistant tuberculosis is a critical problem for pediatricians and tuberculosis prevention and control experts. The authors collected and reviewed domestic and international data on the burden and danger of drug-resistant tuberculosis in children to understand status of drug-resistant tuberculosis in children and timely solve the current problems.

Key words: Tuberculosis, multidrug-resistant, Child, Cost of illness, Risk assessment, Review

李洁琼,申阿东. 儿童耐药结核病的负担与危害[J]. 中国防痨杂志, 2018, 40(9): 989-992. doi: 10.3969/j.issn.1000-6621.2018.09.016

Jie-qiong LI,A-dong SHEN. Burden and detriment of drug-resistant tuberculosis in children[J]. Chinese Journal of Antituberculosis, 2018, 40(9): 989-992. doi: 10.3969/j.issn.1000-6621.2018.09.016

参考文献 30

[1]	World Health Organization. The end TB strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: World Health Organization, 2015.
[2]	World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization, 2017.
[3]	Jenkins HE, Tolman AW, Yuen CM , et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet, 2014,383(9928):1572-1579. doi: 10.1016/S0140-6736(14)60195-1 URL
[4]	Jenkins HE, Yuen CM . The burden of multidrug-resistant tuberculosis in children. Int J Tuberc Lung Dis, 2018,22(5):3-6. doi: 10.5588/ijtld.17.0357 URL pmid: 29665947
[5]	Dodd PJ, Sismanidis C, Seddon JA . Global burden of drug-resistant tuberculosis in children: a mathematical modeling study. Lancet Infect Dis, 2016,16(10):1193-1201. doi: 10.1016/S1473-3099(16)30132-3 URL
[6]	Zignol M, Sismanidis C, Falzon D , et al. Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J, 2013,42(3):701-707. doi: 10.1183/09031936.00175812 URL pmid: 3759300
[7]	Macías Parra M, Kumate Rodríguez J, Arredondo García JL , et al. Mycobacterium tuberculosis Complex Genotype Diversity and Drug Resistance Profiles in a Pediatric Population in Mexico. Tuberc Res Treat, 2011,2011:239042.
[8]	Fairlie L, Beylis NC, Reubenson G , et al. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. BMC Infect Dis, 2011,11:28. doi: 10.1186/1471-2334-11-28 URL
[9]	Kim HJ, Yoon HH, Eun BW , et al. The Rate of Drug-Resis-tant Tuberculosis in Korean Children and Adolescents Since 2007. J Korean Med Sci, 2017,32(6):954-960. doi: 10.3346/jkms.2017.32.6.954 URL pmid: 28480653
[10]	全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012,34(8):485-508.
[11]	Jiao WW, Liu ZG, Han R , et al. Prevalence of drug resistant Mycobacterium tuberculosis among children in China. Tuberculosis (Edinb), 2015,95(3):315-320. doi: 10.1016/j.tube.2015.02.041 URL pmid: 25814302
[12]	彭哲, 刘芮汐, 李奇志 , 等. 儿童结核病耐药状况及危险因素分析. 中国微生态学杂志, 2011,23(7):644-646.
[13]	Tao NN, He XC, Zhang XX , et al. Drug-Resistant Tuberculosis among Children, China, 2006-2015. Emerg Infect Dis, 2017,23(11):1800-1805. doi: 10.3201/eid2311.170234 URL pmid: 29047424
[14]	World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Second Edition. Geneva: World Health Organization, 2014. URL pmid: 17131777
[15]	Falzon D, Schünemann HJ, Harausz E , et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J, 2017, 49(3). pii: 1602308. doi: 10.1183/13993003.02308-2016 URL pmid: 5399349
[16]	Hire R, Kale AS, Dakhale GN , et al. A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India. Mediterr J Hematol Infect Dis, 2014,6(1):e2014061. doi: 10.4084/mjhid.2014.061 URL
[17]	Bhushan B, Chander R, Kajal NC , et al. Profile of adverse drug reactions in drug resistant tuberculosis from Punjab. Indian J Tuberc, 2014,61(4):318-324. URL pmid: 25675695
[18]	王飞, 陈彬, 周琳 , 等. 耐多药肺结核患者抗结核药物所致不良反应发生情况. 中华传染病杂志, 2017,35(2):83-87.
[19]	Mukherjee A, Lodha R, Kabra SK . Current therapies for the treatment of multidrug-resistant tuberculosis in children in India. Expert Opin Pharmacother, 2017,18(15):1595-1606. doi: 10.1080/14656566.2017.1373090 URL
[20]	Hall EW, Morris SB, Moore BK , et al. Treatment Outcomes of Children With HIV Infection and Drug-resistant TB in Three Provinces in South Africa, 2005-2008. Pediatr Infect Dis J, 2017,36(12):e322-e327. doi: 10.1097/INF.0000000000001691 URL
[21]	Chiang SS, Starke JR, Miller AC , et al. Baseline Predictors of Treatment Outcomes in Children With Multidrug-Resistant Tuberculosis: A Retrospective Cohort Study. Clin Infect Dis, 2016,63(8):1063-1071. doi: 10.1093/cid/ciw489 URL
[22]	Ködmön C, van den Boom M, Zucs P , et al. Childhood multidrug-resistant tuberculosis in the European Union and Euro-pean Economic Area: an analysis of tuberculosis surveillance data from 2007 to 2015. Euro Surveill, 2017,22(47). doi: 10.2807/1560-7917.ES.2017.22.47.17-00103.
[23]	Ettehad D, Schaaf HS, Seddon JA , et al. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis, 2012,12(6):449-456. doi: 10.1016/S1473-3099(12)70033-6 URL
[24]	廖琼, 谭珊, 朱渝 , 等. 儿童耐药结核病的临床特点及二线抗结核治疗效果分析. 中华儿科杂志, 2017,55(2):100-103.
[25]	王雪静, 武桂英, 龚幼龙 , 等. 结核病控制项目地区耐药结核病病人经济负担研究. 中国卫生经济, 2005,24(3):49-51.
[26]	Yang C, Luo T, Shen X , et al. Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a re-trospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Infect Dis, 2017,17(3):275-284. doi: 10.1016/S1473-3099(16)30418-2 URL
[27]	Shah NS, Auld SC, Brust JC , et al. Transmission of Extensively Drug-Resistant Tuberculosis in South Africa. N Engl J Med, 2017,376(3):243-253. doi: 10.1056/NEJMoa1604544 URL pmid: 28099825
[28]	Meftahi N, Namouchi A, Mhenni B , et al. Evidence for the critical role of a secondary site rpoB mutation in the compensatory evolution and successful transmission of an MDR tuberculosis outbreak strain. J Antimicrob Chemother, 2016,71(2):324-332. doi: 10.1093/jac/dkv345 URL
[29]	Comas I, Borrell S, Roetzer A , et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet, 2012,44(1):106-110. doi: 10.1038/ng.1038 URL
[30]	Li QJ, Jiao WW, Yin QQ , et al. Compensatory Mutations of Rifampin Resistance Are Associated with Transmission of Multidrug-Resistant Mycobacterium tuberculosis Beijing Genotype Strains in China. Antimicrob Agents Chemother, 2016,60(5):2807-2812. doi: 10.1128/AAC.02358-15 URL

儿童耐药结核病的负担与危害

Burden and detriment of drug-resistant tuberculosis in children

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	刘晓莉, 雷丽梅, 郭周莉, 黄殷, 徐静, 赵霞, 王燕, 付莉. 结核病患者产生病耻感与领悟社会支持的相关性研究[J]. 中国防痨杂志, 2020, 42(9): 1002-1008.
[2]	中国防痨协会学术工作委员会《中国防痨杂志》编辑委员会. 抗结核药品固定剂量复合制剂的临床使用专家共识[J]. 中国防痨杂志, 2020, 42(9): 885-893.
[3]	靳鸿建. 我国县级结核病防治服务体系建设及防治工作亟需加强——一位老防痨工作者的意见和建议[J]. 中国防痨杂志, 2020, 42(9): 896-902.
[4]	张灿有, 夏辉, 成君. Ⅱ级生物安全柜在结核病实验室中的检测及报告要求[J]. 中国防痨杂志, 2020, 42(9): 903-909.
[5]	周林, 刘二勇, 孟庆琳, 陈明亭, 周新华, 高微微, 林明贵, 谢汝明. 《WS 288—2017 肺结核诊断》标准实施后肺结核诊断质量评估分析[J]. 中国防痨杂志, 2020, 42(9): 910-915.
[6]	刘二勇, 王前, 周林, 张国钦, 张修磊, 马永成, 杨枢敏, 王毳, 孟庆琳, 陈明亭, 林明贵, 屠德华. 我国部分地区病原学检测阴性肺结核诊断质量现状分析[J]. 中国防痨杂志, 2020, 42(9): 916-920.
[7]	孟庆琳, 李进岚, 林定文, 马永成, 侯双翼, 刘年强, 周林. 结核病防治从业人员对新的结核病标准相关知识知晓情况调查分析[J]. 中国防痨杂志, 2020, 42(9): 921-925.
[8]	王前, 周林, 刘二勇, 赵雁林, 李涛, 陈明亭, 杨丽佳, 王嘉. 我国县级结核病定点医疗机构结核病诊断能力现况调查研究[J]. 中国防痨杂志, 2020, 42(9): 926-930.
[9]	李婷, 何金戈, 苏茜, 李京, 李运葵, 高文凤, 高媛, 杨文. 结核菌素试验在四川省布拖县HIV感染/AIDS患者中筛查结核感染的价值[J]. 中国防痨杂志, 2020, 42(9): 931-936.
[10]	李运葵, 何金戈, 苏茜, 李婷, 李京, 高文凤, 杨文, 毛光玉. 结核病症状筛查在四川省布拖县HIV感染/AIDS患者中发现结核病患者的价值[J]. 中国防痨杂志, 2020, 42(9): 937-941.
[11]	苏茜, 夏勇, 逯嘉, 王丹霞, 何金戈. 2009—2018年四川省0~14 岁儿童肺结核流行特征分析[J]. 中国防痨杂志, 2020, 42(9): 942-947.
[12]	邓亚丽, 张天华, 刘卫平, 张宏伟, 马煜, 李鹏. 2014—2018年陕西省肺结核发病的时空聚集性分析[J]. 中国防痨杂志, 2020, 42(9): 948-955.
[13]	董晓, 赵珍, 刘年强, 王森路, 崔燕. 2009—2017年新疆维吾尔自治区老年肺结核发现特征分析[J]. 中国防痨杂志, 2020, 42(9): 956-961.
[14]	马廷龙, 韩毅, 程序, 刘志东. 超声抗结核药品电导入联合化疗对胸壁结核的疗效观察[J]. 中国防痨杂志, 2020, 42(9): 968-972.
[15]	南海, 张芸, 杨新婷, 段鸿飞. GeneXpert MTB/RIF对骨关节结核诊断价值的Meta分析[J]. 中国防痨杂志, 2020, 42(9): 973-980.